Studies of macromolecular prodrugs of zidovudine

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 153-164

  Giammona, G ^a   Cavallaro, G ^a   Pitarresi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acquired Immunodeficiency Syndrome (AIDS); Anti HIV drugs; Controlled delivery; Drug carrier; Drug delivery systems; Human Immunodeficiency Virus (HIV); Macromolecular prodrugs; Zidovudine

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; ANTIBODIES; BRAIN; CELLS; MACROMOLECULES; OLIGOMERS; VIRUSES;

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS); HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

ALPHA,BETA POLY(N HYDROXYETHYL)ASPARTAMIDE; DRUG CARRIER; HEPARIN; MONOCLONAL ANTIBODY OX 26; NEOGLYCOPROTEIN; POLYLYSINE; POLYMER; PRODRUG; RECEPTOR ANTIBODY; SUGAR; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE ALPHA,BETA POLY(N HYDROXYETHYL)ASPARTAMIDE CONJUGATE; ZIDOVUDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROMOLECULE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW;

EID: 0032872584     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00024-1     Document Type: Article

References (58)

1. Chin J. Present and future dimension of HIV/AIDS pandemic. Giraldo G., Rossi G.B. Science Challenging AIDS. 1992;33-50 Karger, Basel.
2. Blattner W., Gallo R.C. HIV causes AIDS. Science. 241:1988;515-516.
3. Wells K.H., Poiesz B.J. Biology of retroviruses: detection, molecular biology and treatment of retroviral infection. J. Am. Acad. Dermatol. 22:1990;1175-1195.
4. Mirchardoni H., Chien Y.W. Drug delivery approaches for anti-HIV drugs. Int. J. Pharm. 95:1993;1-21.
5. Haseltine W.A. Replication and pathogenesis of AIDS virus. J. Acquir. Immune Defic. Syndr. 1:1988;217-240.
6. Fauci A.S., Lane H.C. The acquired immunodeficiency syndrome (AIDS). Wilson J.D., Braunwold E., Isselbacher K.J., et al. Harrison's Principles of International Medicine. 12th ed :1991;1402-1410 McGraw-Hill, New York.
7. Hirsch M.S., Curran J. HIV: biology and medical aspects. Fields B.N., Knipe D.M., Channock R.M., et al. Fields Virology. 2nd ed :1990;1545-1570 Raven Press, New York.
8. Levine A.M. AIDS-related malignancies: the emerging epidemic. J. Natl. Cancer Inst. 85:1993;1382-1397.
9. Hammer S.M. Advances in antiretroviral therapy and viral load monitoring. AIDS. 10:1996;1-11.
10. Trono D. Molecular biology and the development of AIDS therapeutics. AIDS. 10:1996;53-59.
11. M. Moroni, A. Lazzarin, Infezioni sistemiche, in: M. Moroni, R. Esposito, F. De Lolla (Eds.), Manuale Delle Malattie Infettive, 4th ed., Masson, 1996, pp. 621-655.
12. De Clercq E. Targets and strategies for the antiviral chemotherapy of AIDS-trends. Pharmacol. Sci. 11:1990;198-205.
13. Richman D.D. Human immunodeficiency virus antiviral therapy. Gorbach S.L., Bartlett J.G., Blacklow N.R. Infections Diseases. 1992;977-998 W.B. Saunders Company, Philadelphia.
14. Rosenblum M.L., Levy R.M. AIDS and the Nervious System. 1988;Raven Press, New York.
15. Matthews S.E., Pouton C.W., Thredgill M.D. Macromolecular systems for chemotherapy and magnetic resonance imaging. Adv. Drug Deliv. Rev. 18:1996;219-267.
16. Duncan R. Drug-polymer conjugation potential for improved chemotherapy. Anti-cancer Drugs. 3:1992;175-210.
17. Kataoka K. Targetable polymeric drugs. Park K. Controlled Drug Delivery: Challenges and Strategies. 1997;American Chemical Society.
18. Molema G., Jansen R.W., Visser J., Herdewijn P., Moolenaar F., Meijer D.K.F. Neoglycoproteins as carriers for antiviral drugs: synthesis and analysis of protein-drug conjugates. J. Med. Chem. 34:1991;1137-1141.
19. Ralapati S., Lee C.M.J., Teodorescu M. Membrane lectins of human lymphocytes. Proceedings, 15th International Leucocyte Culture Conference, Asilomar :1985.
20. Teodorescu M. Binding of bacteria in lymphocyte subpopulations: role of lectin- carbohydrate interactions. Biol. Cell. 51:1984;251-258.
21. Baum L.G., Cresswell P. Isolation and characterization of a galactose-specific carbohydrate binding protein from human lymphoblastic cells. Biochem. Biophys. Res. Commun. 173:1990;1079-1085.
22. Roche A.C., Midoux P., Bouchard P., Monsigny M. Membrane lectins on human monocytes. Maturation-dependent modulation of 6-phosphomannose and mannose receptors. FEBS Lett. 193:1985;63-68.
23. Molema G., Meijer D.K.F. Targeting of drugs to various blood cell types using (neo-)glycoproteins, antibodies and other protein carriers. Adv. Drug Del. Rev. 14:1994;25-50.
24. Kataoka M., Tavassoli M. Synthetic neoglycoproteins: a class of reagents for detection of sugar-recognizing substances. J. Histochem. Cytochem. 32:1984;1091-1098.
25. Dubois M., Gilles A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:1956;350-356.
26. Fiume L., Bassi B., Bongini A. Conjugates of 9-β-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin. Characterization of the drug-carrier bonds. Pharm. Acta Helv. 63:1988;137-139.
27. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorometric assay for the detection of anti-HIV compounds. J. Vir. Methods. 20:1988;309-321.
28. Kuipers M.E., Swart P.J., Hendriks M.M.W.B., Meijer D.K.F. Optimization of the reaction conditions for the synthesis of neoglycoproteins-AZT-Monophosphate conjugates. J. Med. Chem. 38:1995;883-889.
29. Molema G., Jansen R.W., Pauwels R., De Clercq E., Meijer D.K.F. Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem. Pharmacol. 40:(12):1990;2603-2610.
30. Meijer D.K.F., Molema G., Moolenaar F., De Zeeuw D., Swart P.J. (Glyco)-protein drug carriers with intrinsic therapeutic activity: The concept of dual targeting. J. Controlled Rel. 39:1996;163-172.
31. Jansen R.W., Schols D., Pauwels R., de Clercq E., Meijer D.K.F. Novel, negatively charged, human serum albumin display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol. Pharmacol. 44:1993;1003-1007.
32. Jansen R.W., Molema G., Pauwels R., Schols D., De Clercq E., Meijer D.K.F. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol. Pharmacol. 39:1991;818-823.
33. Jansen R.W., Olinga G., Harms G., Meijer D.K.F. Pharmacokinetic analysis and cellular distribution of anti-HIV compound succinylated human serum albumin (suc-HSA) in vivo and in isolated perfused rat liver. Pharm. Res. 10:1993;1611-1614.
34. Fiume, L., Busi, C., Mattioli, A., Baldacci, M. Preparation of conjugates of AZT with human albumin for the targeted treatment of AIDS. Eur. Pat. Appl. EP 503, 741 (C.A.: 239826v, 117, 1992).
35. Uhlmann E., Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90:1990;544-584.
36. Degols G., Leonetti J.P., Benkirame M., Devaux C., Lebleu B. Poly(L-Lysine)-conjugated oligonucleotides promote sequence-specific inhibitor of acute HIV-1 infection. Antisense Res. Dev. 2:1992;298-301.
37. Goodchild J., Agrawal S., Civeira M.P., Sarin P.S., Sun D., Zamecnik P.C. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 85:1988;5507-5511.
38. Gelman R.A., Blackwell J. Heparin-polypeptide interactions in aqueous solution. Arch. Biochem. Biophys. 159:1973;427-433.
39. Morgan D.M.L., Clover J., Pearson J.D. Effects of synthetic polycations on leucine incorporation, lactate dehydrogenase release and morphology of human umbilical vein endothelial cells. J. Cell Sci. 91:1988;231-238.
40. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 85:1988;6132-6136.
41. Moelling K., Schlze T., Diringer H. Inhibition of human immunodeficiency virus type 1 Rnase H by sulfated polyanions. J. Virol. 63:1989;5489-5491.
42. Degols G., Devaux C., Lebleu B. Oligonucleotide-poly(L-lysine)-heparin complexes: potent sequence-specific inhibitors of HIV-1 infection. Bioconjugate Chem. 5:1994;8-13.
43. Friden P.M., Walus L., Musso G., Taylor M., Malfroy B., Starzyk R. Anti-transferrin receptor antibody and antidody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 88:1991;4771-4775.
44. Kumagai A.K., Eisenberg J., Pardridge W.M. Absorptive mediated endocytosis of cationized albumin and a β-endorphin-cationized albumin chimeric peptide by isolated brain capillaries: model of blood-brain barrier transport. J. Biol. Chem. 262:1987;15214-15219.
45. Pardridge W.M., Triguaro D., Buciak J. Transport of histone through the blood-brain barrier. J. Pharmacol. Exp. Ther. 251:1989;821-826.
46. Tadayoni B.M., Friden P.M., Walus L.R., Musso G.F. Synthesis, in vitro kinetics and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconjugate Chem. 4:1993;139-145.
47. Lidinsky W.A., Drewes L.R. Characterization of the blood-brain barrier protein composition of the capillary endothelium cell membrane. J. Neurochem. 41:1983;1341-1345.
48. Giammona G., Carlisi B., Cavallaro G., Donato I., Pinio F., Turco Liveri V. Calorimetric investigation of the interaction between α,β-poly(N-hydroxyethyl)-DL-aspartamide and surfactants. Int. J. Pharm. 64:1990;239-242.
49. Castelli F., Giammona G., Raudino A., Puglisi G. Macromolecular prodrugs interaction with lipid membrane. A calorimetric study of naproxen linked to polyaspartamide interacting with phosphatidylcoline and phosphatidylcholine-phosphatic acid vesicles. Int. J. Pharm. 70:1991;43-52.
50. Giammona G., Carlisi B., Palazzo S. Reaction of α,β-poly(N-hydroxyethyl)-DL-aspartamide with derivatives of carboxylic acids. J. Polym. Sci. Polym. Chem. 25:1987;2813-2818.
51. Neri P., Antoni G., Benvenuti F., Cocola F., Gazzei G. Synthesis of α,β-poly(N-hydroxyethyl)-DL-aspartamide, a new plasma expander. J. Med. Chem. 16:1973;893-897.
52. Giammona G., Cavallaro G., Pitarresi G., Ventura C., Palazzo S. Synthesis and therapeutic potential of a macromolecular prodrug of diflunisal. Int. J. Pharm. 105:1994;57-63.
53. Giammona G., Carlisi B., Pitarresi G., Fontana G. Hydrophilic and hydrophobic polymeric derivatives of antiinflammatory agents such as Alclofenac, Ketoprofen and Ibuprofen. J. Bioact. Compat. Polym. 6:1991;129-141.
54. Giammona G., Puglisi G., Cavallaro G., Spadaro A., Pitarresi G. Chemical stability and bioavailability of acyclovir coupled to α,β-poly(N-hydroxyethyl)-DL-aspartamide. J. Control. Release. 33:1995;261-271.
55. Giammona G., Cavallaro G., Fontana G., De Guidi G., Giuffrida S. Macromolecular prodrugs of diflunisal. II. Investigations of in vitro release and photochemical behaviour. Eur. J. Pharm. Sci. 4:1996;273-282.
56. Giammona G., Cavallaro G., Fontana G., Pitarresi G. Studies of macromolecular prodrug of zidovudine. Proc. 24th Int. Symp. Control. Rel. Bioact. Mater. 1997;1003-1004 Controlled Release Society, Inc.
57. Giammona G., Cavallaro G., Fontana G., Pitarresi G., Carlisi B. Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studies. J. Control. Release. 54:1998;321-331.
58. Martin A. Kinetics. Physical Pharmacy. 4th Ed Physical Chemical Principles in the Pharmaceutical Sciences. 1993;284-323 Lea & Febiger, Philadelphia.